Edoxaban monotherapy reduced net adverse clinical events compared with edoxaban plus a single antiplatelet agent, when used as long-term antithrombotic therapy, in patients with high-risk atrial fibrillation (AF) and stable coronary artery disease (CAD), according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.
Edoxaban monotherapy superior to dual therapy in patients with high-risk AF and stable CAD
- Post author:
- Post published:September 1, 2024
- Post category:uncategorized